Moving on up. Reckons they will move from 1-3 % of USA breast screening mkt.
Investor Newsletter
Printable View
Moving on up. Reckons they will move from 1-3 % of USA breast screening mkt.
Investor Newsletter
Now in trading halt re ethics approval for its acne patient study.
Research note out below too.
Argonaut Snapshot - Clearing Regulatory Hurdles
Sadly depression and suicide on the rise. MEB is well placed to help here.
Medibio Investment Presentation Update
https://youtu.be/hcr7IO_0Sug
Joshuatree
You maybe interested in MDR, MedAdvisor, an app linking in GP's, pharmacies, patients to streamline the script renewal process and allow patients access to manage there own information. Spoke to my GP bout it, but as its Australian, not in use here. NZ has Share Care for Hospitals, After hours and GP's to access certain details.
Can see how this will take off, saves time, money and provides a service I'd personally benefit from.
Thanks; yes its on my watchlist but with over 400 its easily lost in the mix. Cashflow positive 2018 maybe and strong comp from Health Engine and Chemist Warehouse by the looks. Up to 830,000 active users and growing.Be good to be onboard when /if a tipping point gets reached.
VHT
The five-year contract will see both of Imaging Associates’ breast centres benefit from improved image consistency and quality, as well as more accurate radiation dosage, breast compression and personalised breast density assessment for every patient.
So thats why s/p up 27%:)
"Handling 2,500 breast imaging patients annually, this is the first Victorian site to adopt VolparaEnterprise software, and the ninth clinic in Australia to be using a Volpara product."
https://www.biospace.com/News/volpa...l-with-melbourne-based/470987/source=MoreNews
ITD (ITL on ASX) research may be of int
Download
MEB decent agreement with global co Otsuka
BOT
Download Document 108.76KB
"Acne is the most common skin disorder in the US affecting 40-50 million Americans and more than250 million patients worldwide each year. "
- “FDA is very supportive of our approach to conduct well-controlled and regulated clinical studies todemonstrate the safety and efficacy of BTX 1503, and we are excited about the potential for BTX1503 to be one of the first new prescription products to treat acne approved by FDA, in more than20 years.”